DECIMAL: Defining Circadian Metabolism in Non-alcoholic Fatty Liver Disease

Sponsor
University of Oxford (Other)
Overall Status
Recruiting
CT.gov ID
NCT05962099
Collaborator
(none)
31
1
39
0.8

Study Details

Study Description

Brief Summary

The investigators will conduct an open label, experimental medicine study exploring the diurnal patterns of hepatic lipid metabolism in NAFLD and non-NAFLD participants (determined by Transient elastography (TE) with controlled attenuation parameter (CAP)). We will also determine whether the diurnal patterns of lipid metabolism in NAFLD participants can be modified using lifestyle and weight loss intervention. Fourteen participants without NAFLD will have morning and evening metabolic investigations (visit 1M & 1E) to assess for changes in lipid flux pathways across the course of the day. After morning and evening investigations their involvement in the clinical study will then end. Seventeen NAFLD participants will also have identical baseline morning and evening investigation after which they will be enrolled into a 12-week lifestyle and weight loss programme. After 12-weeks, all 17 participants with NAFLD will have a follow up CAP, and morning and evening metabolic investigations (visit 2M & 2E).

Condition or Disease Intervention/Treatment Phase
  • Behavioral: Lifestyle and weight loss advice

Study Design

Study Type:
Observational
Anticipated Enrollment :
31 participants
Observational Model:
Case-Control
Time Perspective:
Prospective
Official Title:
Defining Circadian Metabolism in Non-alcoholic Fatty Liver Disease
Actual Study Start Date :
Mar 1, 2021
Anticipated Primary Completion Date :
Jun 1, 2024
Anticipated Study Completion Date :
Jun 1, 2024

Arms and Interventions

Arm Intervention/Treatment
NAFLD

Behavioral: Lifestyle and weight loss advice
Commercially available lifestyle and weight loss intervention

Controls (non-NAFLD)

Outcome Measures

Primary Outcome Measures

  1. Change in hepatic fatty acid synthesis as measured by incorporation of 2H2 palmitate from 2H2O into very low density lipoprotein triglyceride (VLDL-TG) between morning and evening [12 hours]

Secondary Outcome Measures

  1. Difference in morning and evening glucose production and disposal (of a labelled stable isotope tracer) during a two-step hyperinsulinaemic-euglycaemic clamp [12 hours]

  2. Difference in morning and evening glucose oxidation measured by incorporation of 13C in breath CO2 across a 2-step hyperinsulinemia euglycaemic clamp [12 hours]

  3. Changes in diurnal patterns of hepatic fatty acid synthesis after weight loss programme (measured by incorporation of 2H2 palmitate from 2H2O into very low density lipoprotein triglyceride (VLDL-TG) [12 weeks]

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years to 75 Years
Sexes Eligible for Study:
All
Inclusion Criteria:
  • Male or female

  • BMI 25-50 kg/m2

  • Age 18-75 years

Exclusion Criteria:
  • A diagnosis of type 1 diabetes

  • Type 2 diabetes controlled with medications other than metformin (within last 3 months)

  • Shift working patterns in last 3-months or if likely to work shifts during study period.

  • Current or recent (<3-months) use of weight loss medications

  • Current or recent use of oral contraceptive pill or hormone replacement therapy (within last 3-months)

  • Pregnancy

  • A blood haemoglobin <120mg/dL

  • History of alcoholism or a greater than recommended alcohol intake (Recommendations > 21 units on average per week for men and > 14 units on average per week for women)

  • Haemorrhagic disorders

  • Treatment with anticoagulant agents

  • Other co-morbidities that in the eyes of the investigators may affect data collection

  • Any medical condition in the opinion of the investigator that might impact upon safety or validity of the results

  • Transient elastography (TE) controlled attenuation parameter (CAP) of between 216-305 dB/m

Contacts and Locations

Locations

Site City State Country Postal Code
1 University of Oxford Oxford United Kingdom

Sponsors and Collaborators

  • University of Oxford

Investigators

None specified.

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
University of Oxford
ClinicalTrials.gov Identifier:
NCT05962099
Other Study ID Numbers:
  • 15296
First Posted:
Jul 27, 2023
Last Update Posted:
Jul 27, 2023
Last Verified:
May 1, 2023
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Additional relevant MeSH terms:

Study Results

No Results Posted as of Jul 27, 2023